{"url_path":"/sec/atos/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 LEGAL PROCEEDINGS","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1488039/0001193125-26-213423-index.html","accession_number":"0001193125-26-213423","cik":"0001488039","ticker":"ATOS","issuer_name":"ATOSSA THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1488039/0001193125-26-213423-index.html","primary_entity_key":"0001488039","primary_entity_name":"ATOSSA THERAPEUTICS, INC."},"word_count":93,"has_tables":true,"body_markdown":"ITEM 1. LEGAL PROCEEDINGS\n\nWe are, and from time to time we may become, involved in legal proceedings or be subject to claims arising in the ordinary course of our business. For a discussion of our legal proceedings, refer to Note 12 to the Condensed Consolidated Financial Statements. We are not presently a party to any other legal proceedings that in the opinion of our management, if determined adversely to us, would individually or taken together have a material adverse effect on our condensed consolidated results of operations, financial condition or cash flows."}